Chemokine Receptor 2 Targeted PET/CT Imaging Distant Metastases in Pancreatic Ductal Adenocarcinoma.
Journal
ACS pharmacology & translational science
ISSN: 2575-9108
Titre abrégé: ACS Pharmacol Transl Sci
Pays: United States
ID NLM: 101721411
Informations de publication
Date de publication:
12 Jan 2024
12 Jan 2024
Historique:
received:
26
10
2023
revised:
15
11
2023
accepted:
16
11
2023
pmc-release:
05
12
2024
medline:
17
1
2024
pubmed:
17
1
2024
entrez:
17
1
2024
Statut:
epublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and treatment-refractory malignancies. The lack of an effective screening tool results in the majority of patients being diagnosed at late stages, which underscores the urgent need to develop more sensitive and specific imaging modalities, particularly in detecting occult metastases, to aid clinical decision-making. The tumor microenvironment of PDAC is heavily infiltrated with myeloid-derived suppressor cells (MDSCs) that express C-C chemokine receptor type 2 (CCR2). These CCR2-expressing MDSCs accumulate at a very early stage of metastasis and greatly outnumber PDAC cells, making CCR2 a promising target for detecting early, small metastatic lesions that have scant PDAC cells. Herein, we evaluated a CCR2 targeting PET tracer (
Identifiants
pubmed: 38230294
doi: 10.1021/acsptsci.3c00303
pmc: PMC10789124
doi:
Types de publication
Journal Article
Langues
eng
Pagination
285-293Subventions
Organisme : NIH HHS
ID : S10 OD018515
Pays : United States
Organisme : NIBIB NIH HHS
ID : P41 EB025815
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA244938
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA262506
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA248917
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA091842
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA177670
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA272213
Pays : United States
Organisme : NCI NIH HHS
ID : K12 CA167540
Pays : United States
Organisme : NIH HHS
ID : S10 OD030403
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA235672
Pays : United States
Informations de copyright
© 2023 American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Nat Commun. 2015 May 18;6:7158
pubmed: 25981357
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Bioconjug Chem. 2000 Jul-Aug;11(4):527-32
pubmed: 10898574
Trends Cancer. 2018 Jun;4(6):445-459
pubmed: 29860988
Curr Protoc Pharmacol. 2016 Jun 01;73:14.39.1-14.39.20
pubmed: 27248578
J Nucl Med. 2021 Jun 1;62(6):779-786
pubmed: 33097632
Eur J Radiol. 2017 Jul;92:17-23
pubmed: 28624015
Am J Respir Crit Care Med. 2021 Jan 1;203(1):78-89
pubmed: 32673071
J Vis Exp. 2016 Jul 07;(113):
pubmed: 27501019
Front Cell Dev Biol. 2021 Oct 27;9:748631
pubmed: 34778259
Clin Cancer Res. 2021 Feb 15;27(4):1069-1081
pubmed: 33262135
J Med Chem. 2004 Mar 11;47(6):1465-74
pubmed: 14998334
JAMA. 2013 Oct 9;310(14):1473-81
pubmed: 24104372
Insights Imaging. 2020 Apr 25;11(1):58
pubmed: 32335790
BMC Cancer. 2022 Apr 27;22(1):463
pubmed: 35477379
Cancer Imaging. 2020 Jul 23;20(1):52
pubmed: 32703312
World J Gastroenterol. 2021 Jun 21;27(23):3148-3157
pubmed: 34163103
J Oncol. 2022 Jul 7;2022:8549487
pubmed: 35847365
Cell. 2017 Feb 9;168(4):670-691
pubmed: 28187288
J Microsc Ultrastruct. 2019 Jul-Sep;7(3):136-140
pubmed: 31548925
Pancreas. 2019 Sep;48(8):996-1002
pubmed: 31404025
Front Immunol. 2021 Apr 06;12:612271
pubmed: 33889150
Cell Commun Signal. 2020 May 29;18(1):82
pubmed: 32471499
Lancet Oncol. 2016 May;17(5):651-62
pubmed: 27055731
Oncotarget. 2016 May 10;7(19):28697-710
pubmed: 26885690
Cancer Cell. 2005 May;7(5):469-83
pubmed: 15894267
Circ Cardiovasc Imaging. 2020 Mar;13(3):e009889
pubmed: 32164451
World J Gastroenterol. 2014 Nov 14;20(42):15580-9
pubmed: 25400441
Cell Prolif. 2021 Oct;54(10):e13115
pubmed: 34464477
Circ Res. 2019 Mar 15;124(6):881-890
pubmed: 30661445
Mol Cancer. 2018 Jun 14;17(1):95
pubmed: 29903049
Gut. 2018 Jun;67(6):1112-1123
pubmed: 29196437
J Nucl Med. 2021 Jan;62(1):111-114
pubmed: 32444372
JCI Insight. 2021 Mar 8;6(5):
pubmed: 33497362
J Clin Med. 2021 Mar 10;10(6):
pubmed: 33801810
JAMA Oncol. 2018 Jul 1;4(7):963-969
pubmed: 29800971
Oncoimmunology. 2018 Aug 1;7(9):e1470729
pubmed: 30228938
BMC Cancer. 2020 Aug 10;20(1):744
pubmed: 32778061
STAR Protoc. 2023 Mar 17;4(1):102021
pubmed: 36638017
Radiology. 2017 Jun;283(3):758-768
pubmed: 28045644
J Vis Exp. 2014 Sep 27;(91):51677
pubmed: 25285458
ACS Nano. 2021 Jan 26;15(1):1186-1198
pubmed: 33406361
Cell Rep. 2017 Apr 4;19(1):203-217
pubmed: 28380359
Nat Rev Cancer. 2017 May;17(5):302-317
pubmed: 28303905